Online citations, reference lists, and bibliographies.
← Back to Search

Hyaluronic Acid-based Nanocarriers For Intracellular Targeting: Interfacial Interactions With Proteins In Cancer.

K. Choi, G. Saravanakumar, J. Park, K. Park
Published 2012 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The therapeutic efficacy of most drugs is greatly depends on their ability to cross the cellular barrier and reach their intracellular target sites. To transport the drugs effectively through the cellular membrane and to deliver them into the intracellular environment, several interesting smart carrier systems based on both synthetic or natural polymers have been designed and developed. In recent years, hyaluronic acid (HA) has emerged as a promising candidate for intracellular delivery of various therapeutic and imaging agents because of its innate ability to recognize specific cellular receptors that overexpressed on diseased cells. The aim of this review is to highlight the significance of HA in cancer, and to explore the recent advances of HA-based drug carriers towards cancer imaging and therapeutics.
This paper references
10.1002/IJC.2910440311
Sera of children with renal tumours contain low‐molecular‐mass hyaluronic acid
S. Kumar (1989)
10.1016/j.jconrel.2010.04.004
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.
K. Kim (2010)
10.1515/9783111576855-012
G
G.V.T.V. Weerasooriya (1824)
Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
H. J. Terpe (1996)
Hydrotropic hyaluronic acid conjugates: synthesis
G. Saravanakumar (2010)
10.1074/jbc.272.44.28057
Identification of Hyaluronan-binding Domains of Aggrecan*
H. Watanabe (1997)
10.1158/0008-5472.CAN-05-1022
HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor.
V. Lokeshwar (2005)
10.1111/1523-1747.EP12478553
Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture.
R. Tammi (1991)
10.1002/IJC.2910520102
Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: Comparison between invasive and non‐invasive areas
P. Bertrand (1992)
10.1074/JBC.M011004200
Mouse LYVE-1 Is an Endocytic Receptor for Hyaluronan in Lymphatic Endothelium*
R. Prevo (2001)
10.1038/nrd1088
The dawning era of polymer therapeutics
R. Duncan (2003)
10.1016/j.biomaterials.2008.08.038
Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes.
H. Lee (2008)
10.1126/SCIENCE.2408340
Angiogenesis induced by degradation products of hyaluronic acid.
D. West (1985)
10.1016/j.biomaterials.2010.08.015
Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis.
Yu-Jeong Kim (2010)
10.1038/nrc1391
Hyaluronan: from extracellular glue to pericellular cue
B. Toole (2004)
10.1016/j.biomaterials.2009.09.030
Self-assembled hyaluronic acid nanoparticles for active tumor targeting.
K. Choi (2010)
10.1016/0092-8674(89)90638-7
A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family
I. Stamenković (1989)
10.1124/pr.54.4.561
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Z. Qian (2002)
10.1016/S0002-9440(10)64757-8
Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival.
P. Auvinen (2000)
10.1016/S1359-6101(97)00008-7
TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity.
H. Wisniewski (1997)
10.1002/ADFM.200801164
A Smart Nanoprobe Based On Fluorescence-Quenching PEGylated Nanogels Containing Gold Nanoparticles for Monitoring the Response to Cancer Therapy
Motoi Oishi (2009)
Hyaluronan: its nature
J. R. Fraser (1997)
The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments.
V. Assmann (1999)
10.1002/mabi.200900415
In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes.
K. K. Upadhyay (2010)
10.1038/sj.bjc.6690180
Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate
L. Setälä (1999)
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins.
D. Parker (1995)
Characterization and identification of the hyaluronate binding site from membranes of SV-3T3 cells.
C. Underhill (1985)
Physical characteristics of hyaluronate binding to the surface of simian virus 40-transformed 3T3 cells.
C. Underhill (1980)
10.1002/ijc.10668
Hyaluronidase reduces human breast cancer xenografts in SCID mice
S. Shuster (2002)
10.1084/JEM.177.2.443
Prevention of tumor metastasis formation by anti-variant CD44
S. Seiter (1993)
10.1016/S0140-6736(95)90521-9
CD44 variant exon epitopes in primary breast cancer and length of survival
M. Kaufmann (1995)
10.1084/JEM.186.12.1985
Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function
Q. Yu (1997)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.
T. Strobel (1997)
10.1016/S0022-5347(01)62975-6
Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.
H. Pham (1997)
10.1016/j.semcancer.2008.03.017
Hyaluronidases in cancer biology.
R. Stern (2008)
10.1021/mp800176t
Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
G. Jiang (2009)
10.1158/0008-5472.CAN-04-2805
HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion.
V. Lokeshwar (2005)
10.1158/1078-0432.CCR-04-0349
Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But
D. Coradini (2004)
10.1074/JBC.M202404200
Hyaluronan Oligosaccharides Inhibit Anchorage-independent Growth of Tumor Cells by Suppressing the Phosphoinositide 3-Kinase/Akt Cell Survival Pathway*
S. Ghatak (2002)
10.1016/b978-0-12-384931-1.00016-7
P
J. Lackie (2013)
10.1016/B978-008044382-9/50056-X
Hyaluronan synthases.
P. Weigel (1997)
10.1038/265407a0
Targeting of drugs
G. Gregoriadis (1977)
10.1046/j.1365-2796.1997.00170.x
Hyaluronan: its nature, distribution, functions and turnover
J. E. Fraser (1997)
10.1074/jbc.M608358200
CD44-dependent Intracellular and Extracellular Catabolism of Hyaluronic Acid by Hyaluronidase-1 and -2*
Hosami Harada (2007)
10.1074/JBC.M003084200
Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells.
V. Lokeshwar (2000)
10.1158/0008-5472.CAN-04-2550
Nanoparticle-Aptamer Bioconjugates
O. Farokhzad (2004)
Nanocarriers as an emerging platform for cancer therapy
S. Wise (2007)
10.1084/JEM.174.4.859
Distinct effects of two CD44 isoforms on tumor growth in vivo
M. Sy (1991)
10.3892/OR.10.3.609
Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines.
N. Junker (2003)
10.1593/NEO.07229
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
E. Auzenne (2007)
The over-expression of , and CD44 is implicated in the invasiveness of breast cancer
Lishanthi Udabage (2005)
10.1080/10611860802095494
Preparation and characterization of HA–PEG–PCL intelligent core–corona nanoparticles for delivery of doxorubicin
A. Yadav (2008)
10.1021/BI700382G
Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis.
K. Chao (2007)
10.1002/ijc.11615
Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models
D. Peer (2004)
10.1073/PNAS.81.21.6767
Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis.
W. Knudson (1984)
Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells.
N. Liu (2001)
10.1002/(SICI)1097-0215(19990702)82:1<77::AID-IJC14>3.0.CO;2-Q
Human breast‐cancer metastasis formation in a nude‐mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan‐binding sites in metastatic cells
R. Victor (1999)
10.1021/BC070111O
Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
H. Mok (2007)
10.1021/bc1004119
Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe.
S. Lee (2011)
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity.
C. Underhill (1987)
10.1016/0092-8674(89)90639-9
A human lymphocyte homing receptor, the Hermes antigen, is related to cartilage proteoglycan core and link proteins
L. Goldstein (1989)
Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1.
V. Lokeshwar (1999)
10.1016/J.JCONREL.2004.08.007
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
A. Lukyanov (2004)
10.1016/j.jconrel.2007.12.014
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
J. Kim (2008)
10.1002/CHIN.200916264
Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology
Jinwoo Cheon (2009)
10.1002/BIT.21578
Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment
Woochan Hyung (2008)
10.1083/JCB.99.2.512
A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton
G. Tarone (1984)
10.1016/j.addr.2006.09.009
Multifunctional nanocarriers.
V. Torchilin (2006)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1016/J.ADDR.2003.10.030
Lectin-mediated drug targeting: history and applications.
C. Bies (2004)
10.1074/JBC.M003030200
Identification of the Hyaluronan Receptor for Endocytosis (HARE)*
Bin Zhou (2000)
10.1182/BLOOD-2002-01-0030
Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.
A. Calabro (2002)
10.1016/S0169-409X(02)00042-X
Folate-mediated delivery of macromolecular anticancer therapeutic agents.
Y. Lu (2002)
10.1073/PNAS.76.12.6299
Hyaluronate and invasiveness of the rabbit V2 carcinoma.
B. Toole (1979)
10.1002/ijc.20562
Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B‐cell non‐Hodgkin lymphoma: Relationship with tumor aggressiveness
P. Bertrand (2005)
Hyaluronidase is more elevated in human brain metastases than in primary brain tumours.
B. Delpech (2002)
10.1021/MP050032Z
Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.
S. Sahoo (2005)
Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
R. E. Eliaz (2001)
10.1074/JBC.M313178200
Selective Expression and Functional Characteristics of Three Mammalian Hyaluronan Synthases in Oncogenic Malignant Transformation*
N. Itano (2004)
10.2353/AJPATH.2007.060793
Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M.
H. Koyama (2007)
10.1016/J.NANO.2007.09.004
Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
A. Yadav (2007)
10.1016/J.ADDR.2003.10.017
Drug targeting to the colon with lectins and neoglycoconjugates.
T. Minko (2004)
Biology and Medical Applications of Hyaluronan and its Derivatives
T. Laurent (1998)
LYVE-1a new homologue of the CD44 glycoprotein
S. Banerji (1999)
10.1006/GYNO.1995.1159
Splice variants of CD44 in human cervical cancer stage IB to IIB.
C. Kainz (1995)
10.1021/bc8000485
Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity.
H. Lee (2008)
Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.
V. J. Wielenga (1993)
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.
R. Lee (1994)
10.1080/10408360290795574
CD44 in Cancer
D. Naor (2002)
10.1016/J.UROLONC.2005.08.020
HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer.
A. Rosato (2006)
Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro.
R. Montesano (1996)
10.1515/9783111576855-015
J
Seguin Hen (1824)
Correlated metabolism of proteoglycans and hyaluronic acid in bovine cartilage organ cultures.
T. Morales (1988)
10.1016/J.YEXCR.2005.07.026
The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer.
Lishanthi Udabage (2005)
Structure of human hyaluronidase-1
K. L Chao (2007)
Expression of HYAL2 mRNA
P. Bertrand (2005)
10.1101/GAD.11.8.996
Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation.
G. Kaya (1997)
10.1002/mabi.200800229
Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin.
H. Lee (2009)
10.1016/S0002-9440(10)64273-3
Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells.
Jeanine A Ward (2003)
10.1016/B978-0-12-405191-1.00012-0
Synthesis
P. Wakeley (2013)
10.1038/nrc1566
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.
K. Ropponen (1998)
10.1007/PL00000690
Lecticans: organizers of the brain extracellular matrix
Y. Yamaguchi (2000)
10.1002/ijc.10683
Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors
A. Jacobson (2002)
10.1016/0092-8674(90)90694-A
CD44 is the principal cell surface receptor for hyaluronate
A. Aruffo (1990)
10.1083/JCB.117.6.1343
Correction. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
C. Hardwick (1992)
10.1074/jbc.M008432200
Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer*
V. Lokeshwar (2001)
10.1016/j.ijpharm.2008.07.013
Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand.
S. J. Na (2008)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1083/JCB.144.4.789
LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan
S. Banerji (1999)
10.1016/S0065-2571(00)00013-3
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
10.1002/1529-0131(200108)44:8<1800::AID-ART317>3.0.CO;2-1
Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 (intercellular adhesion molecule 1) invovement.
G. Lisignoli (2001)
10.1016/J.ADDR.2006.09.011
Nanomedicine: developing smarter therapeutic and diagnostic modalities.
O. Farokhzad (2006)
10.1016/S0092-8674(00)80151-8
Solution Structure of the Link Module: A Hyaluronan-Binding Domain Involved in Extracellular Matrix Stability and Cell Migration
D. Kohda (1996)
10.1021/BC9900338
Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate.
Y. Luo (1999)
10.1006/JSRE.2002.6351
Expression of PH-20 in normal and neoplastic breast tissue.
D. Beech (2002)
Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
T. Hirata (1998)
10.1016/J.JPCS.2007.10.052
Preparation and characterization of hyaluronic acid-based hydrogel nanoparticles
K. Choi (2008)
10.1016/j.biomaterials.2009.12.043
The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes.
K. K. Upadhyay (2010)
Develop - ment and characterization of hyaluronic acid - anchored PLGA nanoparticulate carriers of doxorubicin , nanomedicine : nanotechnology
S. Lee (2007)
10.1016/J.EURURO.2004.06.006
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
S. Hautmann (2004)
10.1002/j.1460-2075.1991.tb07955.x
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate‐bearing cells.
I. Stamenković (1991)
10.1002/path.1942
Lymphatic endothelium‐specific hyaluronan receptor LYVE‐1 is expressed by stabilin‐1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis
K. Schledzewski (2006)
10.1002/IJC.2910640307
Expression of cd44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential
E. Manten-Horst (1995)
10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B
HA receptors: Regulators of signalling to the cytoskeleton
J. Entwistle (1996)
10.1016/J.BBAGEN.2006.03.019
Hyaluronidase and CD44 hyaluronan receptor expression in squamous cell laryngeal carcinoma.
T. A. Christopoulos (2006)
Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis.
Q. Hua (1993)
10.1016/J.PROGPOLYMSCI.2007.09.003
Polymeric nanomedicine for cancer therapy
J. Park (2008)
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44.
M. Birch (1991)
10.1002/(SICI)1097-0215(19980729)77:3<396::AID-IJC15>3.0.CO;2-6
Inhibition of tumor growth in vivo by hyaluronan oligomers
C. Zeng (1998)
10.1002/ijc.11252
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors
E. Franzmann (2003)
10.1002/(SICI)1097-0215(19970822)74:4<443::AID-IJC14>3.0.CO;2-A
Soluble CD44 splice variants in metastasizing human breast cancer
S. Martin (1997)
Identity of Hyaluronidase and Spreading Factor
E. Chain (1940)
10.1038/168996B0
Isolation of a Crystalline Disaccharide, Hyalobiuronic Acid, from Hyaluronic Acid
M. Rapport (1951)
10.1074/jbc.R100037200
Hyaluronan and Homeostasis: A Balancing Act*
M. Tammi (2002)
10.1016/0092-8674(91)90403-L
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
U. Guenthert (1991)
10.1016/S0022-5347(05)68050-0
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
V. Lokeshwar (2000)
10.1023/A:1018540610858
CD44 in inflammation and metastasis
J. Lesley (2004)
10.1159/000227497
Prognostic value of CD44 splice variant expression in ovarian cancer.
M. Uhl-Steidl (1995)
10.1074/JBC.M311838200
CD44 Interaction with Na+-H+ Exchanger (NHE1) Creates Acidic Microenvironments Leading to Hyaluronidase-2 and Cathepsin B Activation and Breast Tumor Cell Invasion*
L. Bourguignon (2004)
10.1023/A:1024458206032
Hydrotropic Solubilization of Paclitaxel: Analysis of Chemical Structures for Hydrotropic Property
J. Lee (2004)
Drug delivery and targeting.
R. Langer (1998)
Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent.
M. Zahalka (1995)
Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts.
T. Asplund (1993)
A human lymphocyte homing receptor
L. A. Goldstein (1989)
10.1016/S0168-8278(00)80192-0
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.
K. Endo (2000)
10.1016/0304-4165(72)90160-2
The specific interaction of hyaluronic acid with cartillage proteoglycans.
T. Hardingham (1972)
10.1002/cncr.10652
Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests
V. Lokeshwar (2002)
10.1016/J.JCONREL.2007.02.011
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels.
H. Lee (2007)
10.1016/S0002-9440(10)64245-9
Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice.
M. Simpson (2002)
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
P. Sapra (2002)
10.1016/S0168-3659(01)00315-7
Tumor targeting using anti-her2 immunoliposomes.
J. Park (2001)
10.1158/1078-0432.CCR-07-1228
Targeting Hyaluronan Interactions in Malignant Gliomas and Their Drug-Resistant Multipotent Progenitors
A. G. Gilg (2008)
10.1136/mp.52.4.189
CD44 cell adhesion molecules.
S. Goodison (1999)
10.1039/B900456D
Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution
K. Choi (2009)
10.1016/b978-0-12-384931-1.00003-9
C
J. Lackie (2013)
10.1002/0471684228.egp10550
REAL TIME
E. Dürr (2012)
10.1016/j.ijpharm.2010.04.041
Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel.
G. Saravanakumar (2010)
10.1016/0140-6736(93)92879-X
De-novo expression of CD44 and survival in gastric cancer
B. Mayer (1993)
10.1002/(SICI)1097-0215(19990505)81:3<411::AID-IJC15>3.0.CO;2-F
Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti‐proliferative activity on a breast‐cancer cell line
D. Coradini (1999)
10.1002/ADMA.200800756
Bioinspired Surface Immobilization of Hyaluronic Acid on Monodisperse Magnetite Nanocrystals for Targeted Cancer Imaging.
Yu-han Lee (2008)
10.1006/EXCR.1997.3792
Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro.
Mehdi Rahmanian (1997)
10.1073/PNAS.0601755103
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
O. Farokhzad (2006)
10.1021/CR050247K
Hyaluronidases: their genomics, structures, and mechanisms of action.
Robert H. Stern (2006)
10.2353/AJPATH.2006.060032
Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice.
M. Simpson (2006)
10.1158/0008-5472.CAN-03-0654
Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes
R. E. Eliaz (2004)
Protein expression of CD 44 ( standard and variant isoforms ) in hepatocellular carcinoma : relationships with tumor grade , clinicopatho - logic parameters , p 53 expression , and patient survival
P. Kohlberger (2000)
THE POLYSACCHARIDE OF THE VITREOUS HUMOR
K. Meyer (1934)
Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity.
R. Kosaki (1999)
Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression.
V. Lokeshwar (1996)
10.1016/J.EJPB.2004.02.016
Polysaccharide-decorated nanoparticles.
C. Lemarchand (2004)
10.1016/j.biomaterials.2010.11.010
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
K. Choi (2011)
10.1093/jb/mvn046
Simple primary structure, complex turnover regulation and multiple roles of hyaluronan.
N. Itano (2008)
Hyaluronidase-Sensitive SPIONs for MR/Optical Dual Imaging Nanoprobes
김광명 (2011)
10.1074/jbc.273.18.11342
The Hyaluronan Receptor RHAMM Regulates Extracellular-regulated Kinase*
S. Zhang (1998)
10.1074/jbc.R100036200
Hyaluronan-binding Proteins: Tying Up the Giant*
A. J. Day (2002)
10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1
Increased hyaluronidase levels in breast tumor metastases
P. Bertrand (1997)
10.1073/PNAS.93.15.7832
Expression of hyaluronidase by tumor cells induces angiogenesis in vivo.
D. Liu (1996)
10.1182/BLOOD.V85.10.2885.BLOODJOURNAL85102885
CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.
R. Stauder (1995)



This paper is referenced by
10.1016/j.colsurfb.2015.07.046
Micellar carriers for the delivery of multiple therapeutic agents.
Rajesh Thipparaboina (2015)
10.1016/j.ejpb.2015.09.019
Protamine-based nanoparticles as new antigen delivery systems.
J. V. González-Aramundiz (2015)
10.1016/j.jconrel.2014.12.032
Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.
H. Han (2015)
10.1016/j.colsurfb.2018.05.008
Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma.
Dalia M Kabary (2018)
10.2147/IJN.S62793
Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid
Jing Yao (2014)
10.3389/fonc.2017.00003
Characterization of the Tumor Microenvironment and Tumor–Stroma Interaction by Non-invasive Preclinical Imaging
N. Ramamonjisoa (2017)
Hyaluronic acid-coated nanoparticles as biofunctional pharmaceutical carriers
Abdulaziz Almalik (2013)
10.1016/j.jconrel.2015.09.014
Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
Yumin Oh (2015)
10.1002/ADMI.201700425
Tumor‐Targeting Photothermal Heating‐Responsive Nanoplatform Based on Reduced Graphene Oxide/Mesoporous Silica/Hyaluronic Acid Nanocomposite for Enhanced Photodynamic Therapy
Wenjing Jiang (2017)
10.1002/mabi.201400135
A novel crosslinked hyaluronic acid nanogel for drug delivery.
S. Pedrosa (2014)
10.1016/j.ijbiomac.2017.03.042
Preparation and characterization of a novel polysialic acid-hyaluronan graft copolymer potential as dermal filler.
Jianrong Wu (2017)
Particle engineering for the production of respirable dry powder formulations
F. Martinelli (2016)
10.3389/fbioe.2018.00110
Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy
N. V. Rao (2018)
10.1016/j.ejpb.2015.03.018
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
10.1016/j.actbio.2015.04.010
β-Ga2O3:Cr(3+) nanoparticle: A new platform with near infrared photoluminescence for drug targeting delivery and bio-imaging simultaneously.
Xinshi Wang (2015)
10.1016/B978-0-323-47347-7.00029-X
Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application
S. P. Egusquiaguirre (2016)
10.1039/c7nr03964f
Coumarin-containing thermoresponsive hyaluronic acid-based nanogels as delivery systems for anticancer chemotherapy.
T. F. Stefanello (2017)
10.1155/2015/537560
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery
S. Misra (2015)
10.1016/j.ejps.2017.04.005
Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors
Lydia Ramzy (2017)
10.1016/j.colsurfb.2014.07.021
Quantitative analysis of ligand effects on bioefficacy of nanoemulsion encapsulating depigmenting active.
Nicolas Atrux-Tallau (2014)
10.1016/j.biomaterials.2012.05.029
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer.
K. Choi (2012)
10.4172/2157-7439.1000316
Induction of Cancer Cell Death by Hyaluronic Acid-Mediated Uptake of Cytochrome C
C. Figueroa (2015)
10.1021/bm5017755
Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
H. Han (2015)
10.1016/j.ejps.2013.05.008
Hyaluronan nanocapsules as a new vehicle for intracellular drug delivery.
F. Oyarzun-Ampuero (2013)
10.1016/j.jconrel.2017.03.012
Endogenous inspired biomineral‐installed hyaluronan nanoparticles as pH‐responsive carrier of methotrexate for rheumatoid arthritis
M. M. Alam (2017)
10.1016/j.ejpb.2015.03.032
Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and challenges.
G. Tripodo (2015)
10.1039/C5RA27532F
Mechanisms of cellular uptake with hyaluronic acid—octadecylamine micelles as drug delivery nanocarriers
Lipeng Qiu (2016)
10.1088/1748-605X/aad368
Chitosan/poly(ethylene glycol)/hyaluronic acid biocompatible patches obtained by electrospraying.
Esra Cansever Mutlu (2018)
10.1007/978-981-32-9816-3_16
Nanotechnology: The Future for Cancer Treatment
Yogita Patil-Sen (2019)
10.1007/978-94-017-8896-0_4
Stimuli-Responsive Polymeric Nanocarriers as Promising Drug and Gene Delivery Systems
G. Saravanakumar (2014)
10.1016/j.biomaterials.2017.06.029
Tumor-selective lipopolyplex encapsulated small active RNA hampers colorectal cancer growth in vitro and in orthotopic murine.
L. Wang (2017)
10.1021/nl301309g
A facile, one-step nanocarbon functionalization for biomedical applications.
M. Swierczewska (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar